American Journal of Clinical Dermatology

(The TQCC of American Journal of Clinical Dermatology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-09-01 to 2023-09-01.)
Cutaneous Manifestations of COVID-19: An Evidence-Based Review104
The Skin Microbiome: A New Actor in Inflammatory Acne83
Melasma Treatment: An Evidence-Based Review75
Skin Microbiota and its Interplay with Wound Healing65
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis58
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review55
Sunscreens and Photoaging: A Review of Current Literature55
Female Androgenetic Alopecia: An Update on Diagnosis and Management53
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib53
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study52
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)51
Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients49
Rosacea: New Concepts in Classification and Treatment48
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic48
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments46
Effects of Diet on Acne and Its Response to Treatment46
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program46
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial45
New and Emerging Targeted Therapies for Vascular Malformations45
Skin Microbiome and its Interplay with the Environment44
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review42
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors40
Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption40
Dermatitis Herpetiformis: An Update on Diagnosis and Management39
Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects38
Hailey–Hailey Disease: An Update Review with a Focus on Treatment Data38
A Review of Noninvasive Techniques for Skin Cancer Detection in Dermatology37
Psychosocial Effects of Vitiligo: A Systematic Literature Review37
Diabetic Foot Ulcers: Appraising Standard of Care and Reviewing New Trends in Management37
Twenty Clinically Pertinent Factors/Observations for Percutaneous Absorption in Humans36
Dermatomyositis: An Update on Diagnosis and Treatment35
Erythema Nodosum: A Practical Approach and Diagnostic Algorithm35
The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses31
Ceramides in Skin Health and Disease: An Update30
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies29
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments29
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study29
Characterization and Analysis of the Skin Microbiota in Rosacea: A Case–Control Study28
Optimizing Isotretinoin Treatment of Acne: Update on Current Recommendations for Monitoring, Dosing, Safety, Adverse Effects, Compliance, and Outcomes28
Skin Microbiome as Years Go By28
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study27
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma27
Conjunctival Melanoma: Current Treatments and Future Options26
Rituximab: A Review in Pemphigus Vulgaris26
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis26
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study25
Teledermatology During COVID-19: An Updated Review25
Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?24
Clinical Course and Characteristics of Generalized Pustular Psoriasis24
Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes24
Microbiota in Rosacea23
New Practical Aspects of Sweet Syndrome23
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials23
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions23
A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita23
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options22
Pathophysiology of Generalized Pustular Psoriasis22
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial22
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outco22
Eosinophilic Dermatoses: Recognition and Management21
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study21
Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review21
Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review20
Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy20
Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata20
Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study20
Sensitive Skin Syndrome: An Update20
50 Years of Topical Retinoids for Acne: Evolution of Treatment19
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis19
Deucravacitinib for the Treatment of Psoriatic Disease18
The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World17
Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence17
The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation17
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)17
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma17
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review17
Fabric Selection in Atopic Dermatitis: An Evidence-Based Review17
Cigarette Smoking, Alcohol Consumption, and Risk of Alopecia Areata: A Population-Based Cohort Study in Taiwan17
The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis16
Emerging Therapeutic Options for Chronic Pruritus16
Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions15
The Role of the Microbiome and Microbiome-Derived Metabolites in Atopic Dermatitis and Non-Histaminergic Itch15
New Topical Therapies for Psoriasis14
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey14
Behçet Disease: An Update for Dermatologists14
Clinical Disease Measures in Generalized Pustular Psoriasis14
Impact of Facial Atrophic Acne Scars on Quality of Life: A Multi-country Population-Based Survey14
Investigational Treatments for Epidermolysis Bullosa14
Granulomatous Cutaneous Drug Eruptions: A Systematic Review14